PT - JOURNAL ARTICLE AU - Aziz, Nurin Abdul AU - Twohig, Katherine A AU - Sinnathamby, Mary AU - Zaidi, Asad AU - Aliabadi, Shirin AU - Groves, Natalie AU - Nash, Sophie AU - Thelwall, Simon AU - Dabrera, Gavin TI - Descriptive Epidemiology of SARS-CoV-2 Gamma (P.1/501Y.V3) variant cases in England, August 2021 AID - 10.1101/2022.05.31.22275827 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.31.22275827 4099 - http://medrxiv.org/content/early/2022/05/31/2022.05.31.22275827.short 4100 - http://medrxiv.org/content/early/2022/05/31/2022.05.31.22275827.full AB - Purpose The Gamma variant of SARS-CoV-2, first detected in travellers from Brazil, was found to have high transmissibility and virulence; following this finding, this paper aims to describe the epidemiology of Gamma cases in England from its first detection on 12 February 2021 to 31 August 2021.Methods The demographic analysis of Gamma cases was stratified by travel exposure. Travel-associated cases were further analysed by countries travelled from, stratified by categories set in place by the Red (highest risk countries), Amber, Green (lowest risk countries) travel policy, which was implemented from May to October 2021.Results There were 251 confirmed Gamma cases detected in England in the study period. 35.1% were imported, 5.6% were secondary, and 29.5% were not travel associated. Early cases were predominantly travel-associated, with later cases likely obtained through community transmission. 51.0% of travel-related cases were travellers from Amber countries, and 40.2% had at least one Red country in their journey.Conclusion The Gamma variant has not seen the same expansion as other variants such as Delta, most likely due to Delta out-competing community transmission of Gamma. Findings indicate the travel policy requiring quarantine for Red and Amber list travellers may have also contributed to preventing onward transmission of Gamma.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This surveillance was performed as part of UK Health Security Agency (UKHSA)'s responsibility to monitor COVID-19 during the current pandemic. This study falls within the research activities approved by the UK Health Security Agency Research Ethics and Governance Group. The UK Health Security Agency has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002 to process confidential patient information under Sections 3(i) (a) to (c), 3(i)(d) (i) and (ii) and 3(iii) as part of its outbreak response activities.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis analysis was based on routine individual-level healthcare data, which cannot be made available to others by the study authors.